Philadelphia, PA Clinical Trials Report — June 2026

For Philadelphia residents considering participation in clinical research, June 2026 presents a range of opportunities, including urgent trials nearing their enrollment deadlines and significant new studies from major sponsors. Across Philadelphia, PA, 1,846 clinical trials are currently recruiting participants at 574 research facilities, offering diverse avenues to contribute to medical advancements.

Act Now: Trials Closing Soon

A total of 116 clinical trials in Philadelphia are slated to conclude within the next 90 days, making prompt action essential for interested individuals. Among these, 21 trials are still actively seeking healthy volunteers, offering a chance to contribute to medical science before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke (3 trials)
• Prostate cancer (3 trials)
• Primary graft dysfunction (2 trials)
• Lung cancer (2 trials)
• Myelodysplastic syndromes (2 trials)
• Advanced solid tumor (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Cancer (2 trials)
• Geriatric assessment (2 trials)
• HIV infections (2 trials)

New Research Opportunities Emerge

This month, Philadelphia saw the opening of 27 new clinical trials, a slight increase from the 23 trials that launched in May 2026. This trend continues to show a steady flow of new research, following a six-month pattern of 25 new trials in January, 41 in February, 40 in March, 23 in April, and 26 in May.

June brings several high-profile new trials to Philadelphia, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring two notable Phase 3 studies focused on weight management. NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," is a global, randomized, placebo-controlled study involving 3,600 participants. It investigates the long-term efficacy, safety, and tolerability of aleniglipron once daily for obesity or overweight with a weight-related comorbidity. Similarly, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a randomized, double-blind, placebo-controlled study with 1,100 participants, evaluating aleniglipron in adults with overweight or obesity and Type 2 Diabetes Mellitus.
• Kallyope Inc. is initiating a significant Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• The University of Pennsylvania is sponsoring two large-scale studies focused on preventive health. NCT07636187, "Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters," aims for 16,416 participants to address barriers to completing key health screenings. Another study, NCT07636174, "Colorectal Cancer Screening Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters," seeks 3,888 participants to improve colorectal cancer screening rates.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," a long-term study involving 1,400 participants. This research aims to better understand the health, development, and everyday experiences of people with Down syndrome of all ages over time.

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials), overweight (2 trials), behavior, health (2 trials), and chronic weight management (2 trials). Drug trials account for the largest share of new studies, with 12 new drug trials, followed by 7 behavioral studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 6 of the 27 new trials launched this month are actively seeking healthy volunteers. Across Philadelphia, a total of 176 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Philadelphia's Leading Research Facilities

Philadelphia is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Pennsylvania (313 trials)
• Children's Hospital of Philadelphia (271 trials)
• Thomas Jefferson University Hospital (118 trials)
• Fox Chase Cancer Center (108 trials)
• Thomas Jefferson University (97 trials)
• Hospital of the University of Pennsylvania (82 trials)
• Research Site (48 trials)
• Temple University Hospital (44 trials)
• Temple University (34 trials)
• The Children's Hospital of Philadelphia (33 trials)
• University of Pennsylvania/Abramson Cancer Center (32 trials)
• Jefferson Torresdale Hospital (25 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the University of Pennsylvania and Thomas Jefferson University to specialized pediatric research at Children's Hospital of Philadelphia and oncology studies at Fox Chase Cancer Center and the Abramson Cancer Center.

Broadening Your Search: Nearby Options

While Philadelphia offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Pennsylvania. Cities with active trials include Pittsburgh (22 trials), Smithfield (3 trials), Allentown (3 trials), Erie (2 trials), Duncansville (2 trials), Bethlehem (2 trials), Scottdale (2 trials), and Monroeville (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 27 new trials launched this month, 24 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials include children, and 2 are female-only. Academic institutions continue to play a vital role in Philadelphia's research ecosystem, with the University of Pennsylvania sponsoring the most new studies (7 trials), followed by Children's Hospital of Philadelphia (1 trial) and the Corporal Michael J. Crescenz VA Medical Center (1 trial). Industry sponsors like Kallyope Inc. (2 trials) and Gasherbrum Bio, Inc. (2 trials) are also driving significant research efforts.

As we move through June, Philadelphia's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.